COMMUNIQUÉS West-GlobeNewswire

Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
03/10/2025
– CHS-114, an anti-CCR8 cytolytic antibody, will also be featured in SITC’s upcoming webinar series “Targets for Cancer IO: A Deep Dive” on October 22, 2025 – REDWOOD CITY, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- [...]
Candel Therapeutics to Present at the SITC 2025 Annual Meeting
03/10/2025
NEEDHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
03/10/2025
Company will share data demonstrating CD47 overexpression as key predictive biomarker for response with the Company’s lead candidate, evorpacept, in HER2+ gastric cancer SOUTH SAN FRANCISCO, Calif., Oct. 03, 2025 (GLOBE [...]
Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting
03/10/2025
New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting The data will be the latest of many additions to EVX-01’s [...]
Anathapindika Is Bringing Holistic Health to the US Through a Trio of Unconventional Nutraceutical Formulas
03/10/2025
Anthapindika Health’s Flagship Product Bundle Addresses Overall Health and Well-Being Through Comprehensive Detoxing and Cleansing Fort Lauderdale, FL, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Anathapindika Health has been [...]
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
03/10/2025
WATERTOWN, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated [...]
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
03/10/2025
WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]
BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025
03/10/2025
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its [...]
Anathapindika Health’s Detoxifying Supplements Are Headed to Retailers in the US
03/10/2025
The Company’s Name Comes From Its Root Cause: to Provide Effective, Natural Solutions to Those Battling Health Issues. Soon, American Consumers Will Have Access to Those Solutions. Fort Lauderdale, FL, Oct. 03, 2025 ( [...]
Enara Bio to Reveal DARKFOX, a Novel Cancer-Specific Dark Antigen with Broad-Ranging Therapeutic Potential, in Oral Presentation at SITC 2025
03/10/2025
Oxford, United Kingdom – October 3, 2025. Enara Bio , a biopharmaceutical company pioneering the discovery of novel Dark Antigens® and the development of bispecific T cell engagers for solid tumors, will present two [...]
Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off
03/10/2025
The Company expects to reestablish and announce a new record date as soon as possible ALAMEDA, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage [...]
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025
BRISBANE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today [...]
BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting
03/10/2025
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company [...]
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of [...]
Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds
03/10/2025
Initial closing of approximately $81 million expected to fund current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrants NEW YORK [...]
Cartesian Therapeutics Announces New Employment Inducement Grant
03/10/2025
FREDERICK, Md., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the [...]
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/10/2025
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted eight newly-hired [...]
Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile
03/10/2025
An expansive biomarker study confirmed OV329 delivered statistically significant inhibition of GABA-AT as measured across multiple metrics OV329 matched or exceeded inhibition demonstrated by therapeutic doses of first- [...]
Angelini Ventures Leads €12 Million Follow-On Investment in Serenis, a Fast-Growing Digital Mental and Physical Health Company
03/10/2025
Through its investment, Angelini Ventures aims to promote the expansion and acceleration of Serenis’ digital health and wellbeing services and amplify its leadership in delivering transformative solutions to corporate [...]

Pages